Influencer Marketing - ytlig inspiration eller något djupare?

Title: "Influencer Marketing - Superficial Inspiriation or Something Deeper?" - A qualitative research about the relationship between fashion influencers and their followers from a Consumer Culture Perspective Seminar date: 2018-01-11 Course: FEKH29, Business Administration: Bachelor Degree Project In Marketing Undergraduate Level, 15 Credits Authors: Michelle Da Silva Pereira, Eric Larsson, Oscar Molin Advisor: Jon Bertilsson Key words: Influencer, Follower, Consumer Culture Theory, Brand Relationship, Fashion Purpose: The purpose of this study is to create a better understanding of followers' view of their relationship to fashion influencers and what kind of motives that underlie their reasons to follow, from a Consumer Culture Perspective. Methodology: A qualitative study has been conducted based on semi-structured interviews. An abductive approach with a hermeneutical view has been used as a foundation throughout the study. The collected empirical material is analysed together with theories from existing literature to generate new knowledge. Theoretical perspectives: The essay takes a starting point in the Consumer Culture Theory perspective focusing on "brand relationship" and elements such as Identity, Group Identity and Symbolism. Empirical foundation: Ten semi-structured in-depth interviews have been conducted with young adults that look upon themselves as followers to fashion influencers. The empirical material that was gathered became a foundation for the research analysis. Conclusion: This study has with help of followers subjective opinions contributed to an understanding of their relationhips with fashion influencers. Prominent discoveries have been a model consisting of four types of relationhips between followers and fashion influencers and has raised the question of whether the power ratio should be revalued.Examensarbetets titel: "Influencer Marketing - ytlig inspiration eller något djupare?" - En kvalitativ studie om relationen mellan modeinfluencers och följare ur ett konsumentkulturperspektiv Seminariedatum: 2018-01-11 Kurs: FEKH29, Examensarbete kandidatnivå i marknadsföring, 15 hp Författare: Michelle Da Silva Pereira, Eric Larsson, Oscar Molin Handledare: Jon Bertilsson Fem nyckelord: Influencer, Follower, Consumer Culture Theory, Brand relationship, Fashion Syfte: Studien ämnar att utifrån ett konsumentkulturperspektiv lämna ett kunskapsbidrag som ger en utökad förståelse för följares syn på relationen till modeinfluencers samt vilka motiv som kan tänkas ligga bakom följarskapet. Metod: En kvalitativ studie har genomförts som baserats på semistrukturerade intervjuer. I uppsatsen har en abduktiv forskningsansats tillämpats med ett hermeneutiskt synsätt. Således har insamlad empiri i kombination med befintlig teori genererat ny kunskap. Teoretiska perspektiv: Uppsatsen tar utgångspunkt i CCT-forskning med fokus på "brand relationship" samt beståndsdelar såsom identitet, grupptillhörighet och symbolik. Empiri: Tio semistrukturerade djupintervjuer genomfördes med unga vuxna som anses vara följare till en eller flera modeinfluencers. Det insamlade empiriska materialet har legat till grund för studiens analys. Resultat: Studien har med hjälp av följares subjektiva åsikter bidragit till en förståelse för relationen mellan modeinfluencers och följare. Framträdande upptäckter är bland annat en modell bestående av fyra olika typer av relationer mellan följare och modeinfluencers samt det faktum att maktförhållandet dem emellan eventuellt kan behöva omvärderas

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Hodgkin, 9p24Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response 65 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease

The Third International Symposium on Fungal Stress – ISFUS

Stress is a normal part of life for fungi, which can survive in environments considered inhospitable or hostile for other organisms. Due to the ability of fungi to respond to, survive in, and transform the environment, even under severe stresses, many researchers are exploring the mechanisms that enable fungi to adapt to stress. The International Symposium on Fungal Stress (ISFUS) brings together leading scientists from around the world who research fungal stress. This article discusses presentations given at the third ISFUS, held in São José dos Campos, São Paulo, Brazil in 2019, thereby summarizing the state-of-the-art knowledge on fungal stress, a field that includes microbiology, agriculture, environmental science, ecology, biotechnology, medicine, and astrobiology

First report of clinical, functional, and molecular investigation of chronic granulomatous disease in nine Jordanian families.

International audienceINTRODUCTION: Chronic granulomatous disease is a rare inherited immunodeficiency syndrome caused by mutations in four genes encoding essential nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex components. MATERIAL AND METHODS: Clinical, functional, and molecular investigations were conducted in 15 Jordanian CGD patients from nine families. RESULTS AND DISCUSSION: Fourteen patients were children of consanguineous parents and suffered from autosomal recessive (AR) CGD forms with mutations in the CYBA, NCF1, and NCF2 genes encoding p22phox, p47phox, and p67phox proteins, except for one patient in whom the mutation's location was not found. One patient had an extremely rare X(+)CGD subtype resulting from a novel missense mutation (G1234C) in exon 10 of CYBB. We found a genetic heterogeneity in the Jordanian families with a high frequency of rare ARCGD, probably because consanguineous marriages are common in Jordan. No clear correlation between the severity of the clinical symptoms and the CGD types could be established

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 (ClinicalTrials.gov identifier, NCT02453594) was a single-arm phase II study of pembrolizumab in three cohorts of patients with rrHL, defined on the basis of lymphoma progression after (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV); (2) salvage chemotherapy and BV, and thus, ineligible for ASCT because of chemoresistant disease; and (3) ASCT, but without BV after transplantation. Patients received pembrolizumab 200 mg once every 3 weeks. Response was assessed every 12 weeks. The primary end points were ORR by central review and safety. Results A total of 210 patients were enrolled and treated (69 in cohort 1, 81 in cohort 2, and 60 in cohort 3). At the time of analysis, patients received a median of 13 treatment cycles. Per central review, the ORR was 69.0% (95% CI, 62.3% to 75.2%), and the complete response rate was 22.4% (95% CI, 16.9% to 28.6%). By cohort, ORRs were 73.9% for cohort 1, 64.2% for cohort 2, and 70.0% for cohort 3. Thirty-one patients had a response >= 6 months. The safety profile was largely consistent with previous pembrolizumab studies. Conclusion Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease. (C) 2017 by American Society of Clinical Oncolog